SAN FRANCISCO, CA--(Marketwire - Nov 27, 2012) - Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies for solid tumors, has been named by Campbell Alliance and Windhover as one of the "Top 10 Oncology Projects to Watch" in 2012. Anne Moon, Ph.D., vice president, product development, will be presenting an overview of Jennerex's novel oncolytic immunotherapy JX-929 at the Windhover Therapeutic Area Partnerships Conference in Boston, MA on November 29, 2012.
"We are proud that JX-929 has been recognized as a 'Top Project to Watch,'" said Laurent Fischer, M.D., president and CEO of Jennerex. "JX-929, which is currently being evaluated in Phase 1 clinical trials involving multiple solid tumor types, has a unique mechanism of action that is designed to rapidly de-bulk tumors while providing a durable immune response that may extend survival with limited side effects and, therefore, minimal disruption in patients' quality of life."
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive opportunities in terms of their potential as future products," said David Cassak, vice president, content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
Previously nominated Windhover Top 10 projects have included many development programs that have gone on to establish major partnerships with recognized pharmaceutical companies.
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer. The Company's lead product, Pexa-Vec (JX-594), is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, Pexa-Vec is being tested in the same patient population in combination with sorafenib. Pexa-Vec is also in a Phase 1 clinical trial in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of Pexa-Vec have shown its ability to selectively target and cause destruction of a variety of common solid tumor types and trigger a potent immune response. Pexa-Vec and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through targeted viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Busan, South Korea. For more information about Jennerex, please visit www.jennerex.com.
About Windhover Conferences
Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, "The Tan Sheet," Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation - Policy - Market Access.